HLVX - HilleVax, Inc. Stock Price, Fair Value and News

$2.09

Market Closed as of 18 Sep 2025, 04:00 pm ET

HLVX Stock Valuation Analysis

Valuation

Max Portfolio %

HLVX Price Action

HLVX RSI Chart

HLVX Stock Valuation Analysis

Valuation

Max Portfolio %

HLVX Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HLVX Fundamentals

HLVX Earnings

HLVX Profitability

HLVX Investor Care

Revenue & Growth

How HilleVax, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

About HilleVax, Inc.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
WEBSITE	hillevax.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	62